• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

Research Brief on Acetylcysteine Impurity 3 (CAS: 79560-92-2): Recent Advances and Analytical Insights

Acetylcysteine Impurity 3 (CAS: 79560-92-2) is a critical impurity associated with the production and stability of N-acetylcysteine (NAC), a widely used mucolytic agent and antidote for acetaminophen poisoning. Recent studies have highlighted the importance of characterizing and controlling this impurity to ensure the safety and efficacy of NAC-based pharmaceuticals. This research brief synthesizes the latest findings on the identification, quantification, and toxicological assessment of Acetylcysteine Impurity 3, offering valuable insights for researchers and regulatory professionals in the chemical and pharmaceutical industries.

Recent analytical advancements have enabled more precise detection and quantification of Acetylcysteine Impurity 3. High-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS) has emerged as the gold standard for its identification, with detection limits as low as 0.1% in NAC formulations. Studies published in the Journal of Pharmaceutical and Biomedical Analysis (2023) have validated these methods, emphasizing their robustness in compliance with ICH Q3A and Q3B guidelines. Furthermore, stability studies indicate that this impurity tends to form under oxidative stress conditions, necessitating stringent storage protocols for NAC products.

From a toxicological perspective, recent in vitro and in vivo studies have shed light on the potential risks associated with Acetylcysteine Impurity 3. Research conducted by the European Medicines Agency (EMA) in 2024 suggests that while the impurity exhibits low acute toxicity, chronic exposure at levels above 0.5% may lead to renal tubular damage in preclinical models. These findings underscore the need for rigorous impurity profiling during drug development and post-marketing surveillance. Additionally, novel synthetic pathways for NAC have been explored to minimize the formation of this impurity, with promising results from enzymatic synthesis approaches reported in Nature Communications (2024).

The regulatory landscape surrounding Acetylcysteine Impurity 3 continues to evolve. The U.S. Pharmacopeia (USP) has proposed new monograph revisions in 2024, setting stricter limits for this impurity in NAC formulations. Concurrently, the development of reference standards for Acetylcysteine Impurity 3 has facilitated more accurate method validation across laboratories. These developments are particularly relevant for generic drug manufacturers seeking ANDA approvals, as regulatory agencies increasingly focus on impurity control as a critical quality attribute.

Looking ahead, several research gaps remain to be addressed. The precise mechanism of Acetylcysteine Impurity 3 formation under various stress conditions requires further elucidation. Moreover, the potential synergistic effects of this impurity with other degradation products in NAC formulations warrant comprehensive safety assessments. Collaborative efforts between academia, industry, and regulatory bodies will be essential to establish standardized testing protocols and safety thresholds for this critical impurity in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)